[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574082":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":43,"responsibleParty":60,"collaborators":26,"id":62,"slug":26,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Pontificia Universidad Catolica de Chile","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Infusion","ACTIVE_COMPARATOR","Patients infusion rate will be set to 4 ml\u002Fh, with 5 ml boluses (30-minute lockout). The PCA button will be disabled for rescue bolus administration.",[13],"Procedure: Single injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Bolus","EXPERIMENTAL","Patients infusion rate will be set to 0 ml\u002Fh, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration.",[19],"Procedure: Continuous perineural infusion",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Continuous perineural infusion","infusion rate 4 ml\u002Fh, with 5 ml boluses (30-minute lockout). The PCA button disabled",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Single injection","infusion rate 0 ml\u002Fh, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration",[9],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Fernando R Altermatt, MD","CONTACT","56955049115","9115","falterma@uc.cl",{"name":39,"role":34,"phone":40,"phoneExt":41,"email":42},"Victor Contreras, MSN","56223543414","3414","vecontre@uc.cl",[44],{"facility":45,"status":46,"city":47,"state":26,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Red de Salud UC Christus","RECRUITING","Santiago","8330024","Chile","CL",{"type":52,"coordinates":53},"Point",[54,55],-70.64827,-33.45694,{"lat":55,"lon":54},[58],{"name":39,"role":34,"phone":59,"phoneExt":26,"email":42},"56981895232",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100574082",false,"NCT06754657","CORA-Q15: Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery","Comparison of Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery: A Randomized Study Assessing Non-inferiority and Superiority (CORA-Q15)","CORA-Q15","Inclusion Criteria:\n\n* Adults (≥18 years, \\\u003C 75 years) scheduled for elective outpatient arthroscopic rotator cuff repair surgery.\n* Patients capable of managing a continuous outpatient regional analgesia system based on an interscalene block (eligibility criteria: able to understand verbal and written instructions, have home support, and live geographically close to the healthcare center).\n* Willing and able to provide informed, written consent to participate in the study.\n\nExclusion Criteria:\n\n* History of chronic opioid use (\\>3 months).\n* Severe comorbidities (e.g., renal or hepatic failure, ASA classification of 3 or higher).\n* Allergy to local anesthetics, dexamethasone, or the analgesic drugs used in the study.\n* Patients with contraindications for peripheral nerve block.","ALL","18 Years","75 Years",{"count":73,"type":74},150,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The purpose of the study will be to compare the efficacy of single-injection interscalene block versus continuous interscalene block on the quality of recovery in patients undergoing outpatient arthroscopic rotator cuff repair surgery.\n\nThe participants will:\n\n* Be randomized to receive either a single-injection interscalene block or continuous infusion via an elastomeric pump.\n* Be monitored via telephone by the research team to complete the QoR-15 survey, assess pain levels, the need for tramadol use, and any complications.\n* Have follow-up by the Acute Pain Unit during the first 3 days.",[80,81,82],"Arthropathy Shoulder","Pain, Acute","Anesthesia",[84,85,86],"ambulatory surgery","rotator cuff repair","regional anesthesia","2025-05-26",{"date":89,"type":90},"2025-05-30","ACTUAL",{"date":87,"type":90},{"date":93,"type":74},"2027-03-31",{"name":5,"class":6},1]